Obeticholic Acid
Cross-source consensus on Obeticholic Acid from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Dosage & preparation
Highlighted claims
- Obeticholic acid is a first-in-class farnesoid X receptor agonist currently licensed as second-line therapy added to UDCA after UDCA failure. — Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid
- OPERA tests whether high-risk patients should receive OCA at the start of treatment rather than after a year of demonstrated UDCA non-response. — Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid
- Participants in the trial receive OCA or placebo at 5 mg once daily until week 12, then may titrate to 10 mg once daily through week 26 according to tolerability. — Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid
- Preclinical cholestasis and human cell culture models suggest OCA can reverse cellular senescence. — Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid